HeartBeam (NASDAQ:BEAT) Upgraded to Sell at Wall Street Zen

Posted by George Bondi on Oct 11th, 2026

Wall Street Zen upgraded shares of HeartBeam (NASDAQ:BEAT – Free Report) to a sell rating in a research report released on Saturday,Wall Street Zen reports.

A number of other research analysts have also recently commented on BEAT. HC Wainwright reaffirmed a “neutral” rating on shares of HeartBeam in a research note on Tuesday. Maxim Group began coverage on HeartBeam in a research note on Tuesday, July 14th. They set a “buy” rating and a $2.00 price target for the company. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of HeartBeam in a report on Tuesday, September 29th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $4.00.

View Our Latest Report on HeartBeam

HeartBeam Trading Down 1.7%

HeartBeam stock opened at $0.48 on Friday. The firm has a 50-day moving average price of $0.47 and a 200-day moving average price of $0.71. The firm has a market capitalization of $27.06 million, a PE ratio of -0.94 and a beta of -0.76. HeartBeam has a 12-month low of $0.35 and a 12-month high of $4.00.

HeartBeam (NASDAQ:BEAT – Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The medical research company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.01). As a group, sell-side analysts predict that HeartBeam will post -0.37 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in shares of HeartBeam in the 2nd quarter valued at about $741,000. Sigma Planning Corp lifted its position in shares of HeartBeam by 86.9% in the 2nd quarter. Sigma Planning Corp now owns 247,700 shares of the medical research company’s stock worth $186,000 after purchasing an additional 115,150 shares during the period. Finally, Beacon Pointe Advisors LLC bought a new position in shares of HeartBeam during the second quarter valued at approximately $185,000. Hedge funds and other institutional investors own 7.77% of the company’s stock.

About HeartBeam

(Get Free Report)

HeartBeam, Inc is a medical technology company developing portable cardiac-monitoring solutions designed to help detect and evaluate heart conditions outside traditional clinical settings. Its technology is intended to provide patients and healthcare professionals with more comprehensive electrocardiogram (ECG) information than conventional single-lead wearable devices.

The company’s primary product is the HeartBeam AIMIGo system, a compact, cable-free device that records a three-dimensional, vector-based ECG.